[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccines and genetics", "description": "Australian vaccine\n\nhttps://www.smh.com.au/politics/federal/australian-covid-vaccine-terminated-due-to-hiv-false-positives-20201210-p56mju.html?utm_source=Nature+Briefing&utm_campaign=dd61a8472e-briefing-dy-20201211&utm_medium=email&utm_term=0_c9dfd39373-dd61a8472e-44762053\n\nUniversity of Queensland\n\nFifty million doses ordered by government\n\n200 volunteers in two groups\n\nAged 18 to 55, and 56 and over, placebo\n\nPhase one trial\n\nSafe and said it produced a strong immune response \n\nTrial terminated; $ 4.5 m (US) lost\n\nSeveral participants, false positive HIV test results\n\nNo health risks\n\n20 million new doses from Oxford University-AstraZeneca and another 11 million from Novavax\n\nUS rollout\n\nGeneral Gustave Perna\n\nFactory, Kalamazoo, Michigan\n\nFlight and road\n\n-70 degrees Celsius (-94F)\n\nFirst doses of vaccine arriving at 145 sites Monday\n\nTuesday, 425 sites\n\nWednesday, 66 sites\n\nHalf of 6.4 million doses sent out\n\nPfizer, 50 million in 2020, half to the US\n\nUS, 100 million doses\n\nApproved for 16 years and older\n\nMassachusetts-based Moderna, increasing vaccinations to 20 million Americans in 2020\n\nFollowed by 200 million Moderna doses\n\nEveryone by June 2021\n\nChina vaccine\n\nInactivated\n\nhttps://www.bbc.co.uk/news/world-asia-china-55212787\n\nSinovac, Beijing, CoronaVac\n\nArrived in Indonesia, (Turkey, Brazil, Chile)\n\nAnother 1.8 m doses due to arrive by January\n\nFridge temperatures\n\nPhase 3 results 15th December\n\nProduction 300 m per year\n\nAfrican continent, $2bn\n\nLatin American and Caribbean, $1bn\n\nCost?\n\nModerna, 500 million doses in 2021\n\nAstraZeneca, 700 million doses by April\n\nUK, Christmas five-day relaxation period\n\nhttps://www.bbc.co.uk/news/uk-wales-55279371\n\nTravel from high to low risk areas\n\nUp to three households can stay together, \"Christmas bubble\" from 23 to 27 December\n\nAll four UK nations\n\nGenetic predisposition\n\nhttps://www.bbc.co.uk/news/health-54832563\n\nGenetic mechanisms of critical illness in Covid-19 Nature, Edinburgh)\n\nhttps://www.nature.com/articles/s41586-020-03065-y\n\nSusceptibility to viral infection\n\nPropensity to develop harmful pulmonary inflammation.\n\nGenetic factors in:\n\nSusceptibility to life threatening infections\n\nImmune-mediated diseases\n\nHost genetic variants\n\nGenome-wide association study\n\nN = 2, 244 critically ill Covid-19 patients\n\nFrom 208 UK intensive care units\n\nGenome-wide significant associations\n\nPotential for repurposing of licensed medications\n\nAssociations with severe COVID\n\nLow expression of IFNAR2 (Chromosome 21)\n\nResults in lower production of interferon\n\nAccounted for nearly 15% of critical Covid-19 cases\n\nInterferons interfere with viral replication\n\nProduce antiviral enzymes to prevent viral replication\n\nInhibit protein synthesis\n\nStimulate local immune cells\n\nCause fever, muscle aches and general malaise\n\nInterferon would need to be given early\n\nWHO SOLIDARITY trial\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments\n\nInterferon had little or no effect on overall mortality, initiation of ventilation and duration of hospital stay in hospitalized patients\n\nNebulised interferon beta-1a for patients with COVID-19 (12th November)\n\nhttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30523-3/fulltext\n\nHigh expression of TYK2 (Chromosome 19)\n\nUp regulation of inflammation\n\nRheumatoid arthritis drug, Baricitinib targets this biological mechanism\n\nLarge-scale randomised clinical trials will be essential", "link": "https://www.youtube.com/watch?v=2lA5_WxP5nQ", "date_published": "2020-12-13 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Croatia, special report", "description": "Special report from Croatia, thank you very much Danko", "link": "https://www.youtube.com/watch?v=3grsMELjZA8", "date_published": "2020-12-12 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Ivermectin and COVID 19", "description": "Ivermectin\n\nhttps://bnf.nice.org.uk/drug/ivermectin.html#indicationsAndDoses\n\nInvitro antiviral activity\n\nAgainst a broad range of viruses\n\nHIV, dengue, influenza, Zika virus\n\nInvitro antiviral, SARS-CoV-2 activity\n\n99.8% reduction in viral RNA after 48 h\n\nWorldwide use for treating COVID-19\n\nAbout 3.7 billion doses of ivermectin have been distributed globally over the past 30 years\n\nEVMS CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL \n\nhttps://www.evms.edu/media/evms_public/departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf\n\nPreexposure prophylaxis in high-risk patients\n\nPostexposure prophylaxis\n\nSymptomatic patients at home\n\nMildly symptomatic patients in hospital \n\nProgressive Respiratory symptoms\n \nIvermectin has emerged as the \u201cwonder drug\u201d to prophylaxis and treat COVID-19\n\nIvermectin inhibits viral replication and has potent anti-inflammatory properties \n\nThere is the potential for serious drug-drug interaction\n\nAdditional, studies are urgently required to confirm these very impressive preliminary findings\n\nReview of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19  (7th December)\n\nhttps://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf\n\nFront Line COVID-19 Critical Care Alliance (FLCCC) \n\nOne Sentence Summary \n\nReview of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19. \n\nUse of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019\n\nThe ICON Study (October 2020, South Florida)\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/\n\nResearch Question\n\nDoes ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?\n\nStudy Design and Methods\n\nConsecutive patients hospitalized\n\nFour hospitals in Florida\n\nConfirmed COVID-19 \n\nMarch 15 and May 11, 2020\n\nTreated with or without ivermectin\n\nPrimary outcome\n\nAll-cause in-hospital mortality\n\nSecondary outcomes, mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, length of stay\n\nSevere pulmonary involvement\n\nNeed for Fio2 \u2265 50%, noninvasive ventilation\n\nInvasive ventilation\n\nResults from reviews\n\nN = 280\n\nIvermectin treated = 173\n\nOverall mortality 15%\n\nMortality with severe pulmonary involvement = 38.8%\n\nNot given ivermectin = 107\n\nOverall mortality 25% (OR, 0.52)\n\nMortality with severe pulmonary involvement = 80.7%\n\nNo significant differences were found in extubation rates or length of stay\n\nMost patients in both groups also received hydroxychloroquine, azithromycin, or both\n\nInterpretation\n\nIvermectin treatment was associated with lower mortality during treatment of COVID-19 \n\nEspecially in patients with severe pulmonary involvement\n\nRandomized controlled trials are needed to confirm these findings\n\nIvermectin news\n\nhttps://www.newswise.com/coronavirus/flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment", "link": "https://www.youtube.com/watch?v=BLWQtT7dHGE", "date_published": "2020-12-12 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Weekend update, 12 - 13 December", "description": "Global\n\nCases, 69,833,475\n\nDeaths, 1,587,024\n\nMost cases per million\n\nLuxembourg\n\nLithuania\n\nGeorgia\n\nCroatia\n\nSerbia\n\nSan Marino\n\nMontenegro\n\nSlovenia\n\nSweden\n\nBelize\n\nUnited states\n\nCzechia\n\nInternational situation live map\n\nhttps://health-infobase.canada.ca/covid-19/international/\n\nUK\n\nSelf-isolation for contacts of confirmed cases, 10 days from Monday, all UK\n\nDay 10, 2% still capable of passing on the virus\n\nAlso quarantine returning from high-risk countries\n\nCases falling in most of England and Northern Ireland\n\nWeek ending 5 December\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19roundup/2020-03-26#health\n\nEngland, 481,500 infections in the week\n\nOne in 115\n\nScotland, one in 120\n\nWales, one in 120\n\nNI, one in 235\n\nIncreased case, London and East of England\n\nPositivity rates down in other regions in England and Wales\n\nR number back up to 0.9 \u2013 1\n\nDeaths, W/E 27th November\n\nCOVID-19 deaths increased for 12 week\n\nIn the week, 3,040 (24.4% of deaths)\n\nUnited states\n\nRobert Redfield\n\nCoronavirus will kill more every day for the next 60 to 90 days than Sept. 11, 2001\n\nor Pearl Harbor\n\nDeaths, 3,140 + 3,300 = 291,800\n\nWW2\n\nUS Food and Drug Administration\n\nRecommended emergency approval, Pfizer/BioNTech vaccine. \n\nStill needs to be formally approved by the FDA's vaccine chief\n\nOperation Warp Speed, vaccine deliveries will begin with 24 hours of approval. \n\nPlans to rollout the vaccine are already underway. The United Parcel Service and FedEx are working with the government to send the vaccine to distribution staging areas.\n\nVaccine needs to be kept in a cold freezer and must be used quickly once it has thawed.\n\nPfizer, 6.4 million doses ready\n\nMass rollout, March or April\n\nRussia\n\nCases, + 27,927 + 28,585 = 2,059,840\n\nDeaths, + 562 + 613 = 45,893\n\n(Russia's coronavirus headquarters)\n\nSputnik and alcohol\n\nAnna Popova, head of the consumer health watchdog\n\nKomsomolskaya Pravda radio station\n\nStop drinking at least two weeks before first injections\n\nThree weeks between shots\n\nContinue to abstain for a further 42 days\n\nAlcohol would reduce the body\u2019s ability to build up immunity\n\nIt\u2019s a strain on the body. If we want to be healthy and have a strong immune response, don\u2019t drink alcohol\n\nAlexander Gintsburg, vaccine developer\n\nOne glass of champagne won\u2019t hurt anyone, not even your immune system\n\nPrudent to reduce alcohol use by a reasonable amount while the body built up immunity, \nno need to give up completely.\n\nCrucial however\n\nThree days before and two days after\n\nGeneral advice\n\nMass rollout\n\nMoscow\u2019s Polyclinic No. 3\n\nMoscow clinic, No. 3 Branch 2\n\nInformation, government officials or vaccine developers\n\nSputnik V vaccine efficacy exceeds 95 percent and it is safe\n\nMoscow\u2019s deputy mayor, Anastasia Rakova, Phase 3 report\n\nRCT, n = 40,000\n\nQuarter get placebo\n\n20,000 people had received both shots\n\n272 got the virus\n\nNo serious side effects", "link": "https://www.youtube.com/watch?v=noaTw8a_5gQ", "date_published": "2020-12-12 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]